New developments in antitumor anthracyclines. 1997

F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
Menarini Ricerche, Rome, Italy.

Doxorubicin is a major anticancer agent introduced to extended clinical use in the early 1970s. The fulfillment of a wide program of analogue synthesis led to the development of the better tolerated epirubicin and of a highly potent antileukemic drug, idarubicin. In recent years, on the basis of the available information on the molecular requirements for action, a new synthetic program, coupled with target-oriented pharmacological experiments, was carried out. Various interesting derivatives, namely, the 8- and 10-fluoro compounds and the disaccharides, were obtained. The latter compounds exhibited a strong dependence of biological activity on the orientation (axial vs. equatorial) of the second sugar moiety, daunosamine. A member of this group, namely, 7-O-(4'-O-alpha-L-daunosaminyl-2'-deoxy-alpha-L-fucosyl)-4-demetho xy-adriamycinone, is presently undergoing clinical trials as a third generation antitumor anthracycline.

UI MeSH Term Description Entries
D008958 Models, Molecular Models used experimentally or theoretically to study molecular shape, electronic properties, or interactions; includes analogous molecules, computer-generated graphics, and mechanical structures. Molecular Models,Model, Molecular,Molecular Model
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D000903 Antibiotics, Antineoplastic Chemical substances, produced by microorganisms, inhibiting or preventing the proliferation of neoplasms. Antineoplastic Antibiotics,Cytotoxic Antibiotics,Antibiotics, Cytotoxic
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs

Related Publications

F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
January 1984, Medicinal research reviews,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
January 1977, Lloydia,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
August 2001, Current medicinal chemistry. Anti-cancer agents,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
December 1985, Cancer research,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
June 2004, Pharmacological reviews,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
April 1988, The Journal of antibiotics,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
December 1989, The Journal of antibiotics,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
September 1977, The Journal of antibiotics,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
January 1986, Anticancer research,
F Arcamone, and F Animati, and G Capranico, and P Lombardi, and G Pratesi, and S Manzini, and R Supino, and F Zunino
January 1987, Advances in applied microbiology,
Copied contents to your clipboard!